ArticleMedicine2025
Identification of hub genes and potential molecular mechanisms related to radiotherapy in thyroid cancer.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy is a common approach during the treatment of thyroid cancer (THCA). It is urgent to identify the radiotherapy-related gene and explore the underlying mechanisms. An message RNA expression clinical data was gained from the Cancer Genome Atlas. The differential expression genes between normal individuals and THCA patients were identified by the "limma" package of R software. The differential expression genes between the patients without radiation therapy and the patients with radiation therapy were also obtained via the same method. Survival analysis, gene set enrichment analysis, immune analysis, drug sensitivity analysis, gene-miRNA, and nomogram analysis were performed to explore the radiotherapy-related gene value. The results showed that 354 DGEs between the THCA patients without radiation therapy and THCA patients with radiation therapy including the 148 up-regulated genes and 206 down-regulated were screened and displayed by volcano plot. A gene enrichment analysis showed radiation-related genes were enriched in various pathways such as mineral absorption, complement and coagulation cascades, B cell receptor signaling pathway, salivary secretion, and hematopoietic cell lineage. Then the hub-related-radiotherapy prognosis gene LRP1B was identified. The expression analysis showed that the LRP1B expression level was higher in normal individuals than in THCA patients with an obvious difference via T test in independent samples and paired samples. Immune analysis results showed that the stroma score, immune score, and ESTIMATES score were higher in the low-risk score than in the high-risk score. LRP1B is a vital gene that executes function via a variety of pathways in THCA patients with radiotherapy. Radiotherapy could reduce the expression of LRP1B and AL356596.1. Moreover, the constructed nomogram is based on risk score and clinical features, and it had a great function in predicting survival time for patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.